![tianpeipei目前处于离线状态](https://user.hlgnet.com/face/Image1.gif) |
等 级:长老 |
经 验 值:886 |
魅 力 值:150 |
龙 币:4830 |
积 分:1878.4 |
注册日期:2007-05-25 |
|
|
|
刚用英文搜索了,2-5岁最好用7价,23价可以用在体质弱的2岁上孩子和打过7价后需要加强的.
真希望23价有效,毕竟价格便宜多了,但是2-5岁的孩子和成人用一样的疫苗,就是担心孩子免疫反应重.
Note: Children from 2 to 5 years of age may receive pneumococcal poly-saccharide 23-valent vaccine, but the pneumococcal conjugate vaccine is generally preferred because of the age-dependent response. Polysaccharide vaccine may be used both as a booster dose in this age group and to increase the serotype coverage. Pneumococcal polysaccharide vaccine is not indicated for use in children < 2 years of age, in whom the pneumococcal conjugate vaccine should be used for routine prevention of invasive pneumococcal disease, commencing at 2 months of age.
Pneumovax 23 is recommended for:
6.1.1 All individuals aged 65 years and over (funded).
6.1.2 Aboriginal and Torres Strait Islander (ATSI) people aged 50 years and over and those ATSI people aged 15-49 years who have chronic cardiac, renal or pulmonary disease, diabetes mellitus and alcoholism or tobacco smokers (funded)
6.1.3 Individuals with asplenia, either functional or anatomical, including sickle cell disease, in persons more than 2 years of age; where possible the vaccine should be given at least 14 days before splenectomy (not funded)
6.1.4 Immunocompromised persons with increased risk of pneumococcal disease (eg: patients with HIV infection before the development of AIDS, nephrotic syndrome, multiple myeloma, Hodgkin’s Disease and organ transplantation) (not funded)
6.1.5 Immunocompetent persons at increased risk of complications from pneumococcal disease because of chronic illness (eg: chronic cardiac, renal or pulmonary disease, diabetes mellitus and alcoholism) (not funded)
6.1.6 Patients with cerebrospinal fluid leaks (not funded)
6.1.7 Tobacco smokers (not funded)
6.1.8 As a booster dose, at 2 years of age, following a course of 7vPCV, in ATSI children (funded
6.1.9 As a booster dose, at 4-5 years of age, following a course of 7vPCV, in children with predisposing medical conditions as listed in the Handbook1 (funded)
|
|
|
|